These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 35903020)

  • 1. Development and prognosis of hepatocellular carcinoma in patients with diabetes.
    Nakatsuka T; Tateishi R
    Clin Mol Hepatol; 2023 Jan; 29(1):51-64. PubMed ID: 35903020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin Use and The Risk of Hepatocellular Carcinoma: Insights and Implications.
    Kurniawan J; Teressa M
    Acta Med Indones; 2024 Jan; 56(1):107-113. PubMed ID: 38561879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The Development of Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease].
    Kwon OS; Kim JH; Kim JH
    Korean J Gastroenterol; 2017 Jun; 69(6):348-352. PubMed ID: 28637103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.
    Chen J; Song S; Li X; Bian D; Wu X
    Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease: Definition and subtypes.
    Han SK; Baik SK; Kim MY
    Clin Mol Hepatol; 2023 Feb; 29(suppl):S5-S16. PubMed ID: 36577427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population.
    Kogiso T; Sagawa T; Kodama K; Taniai M; Hashimoto E; Tokushige K
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1579-1589. PubMed ID: 31975453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.
    Seif El Dahan K; Daher D; Singal AG
    Clin Mol Hepatol; 2023 Feb; 29(Suppl):S207-S219. PubMed ID: 36103899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives.
    Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.
    Margini C; Dufour JF
    Liver Int; 2016 Mar; 36(3):317-24. PubMed ID: 26601627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE.
    Cavalcante LN; Dezan MGF; Paz CLDSL; Lyra AC
    Arq Gastroenterol; 2022; 59(4):540-548. PubMed ID: 36515349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.
    Ueno M; Takeda H; Takai A; Seno H
    World J Gastroenterol; 2022 Jul; 28(27):3410-3421. PubMed ID: 36158261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
    Noureddin M; Rinella ME
    Clin Liver Dis; 2015 May; 19(2):361-79. PubMed ID: 25921668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.
    Chrysavgis L; Giannakodimos I; Diamantopoulou P; Cholongitas E
    World J Gastroenterol; 2022 Jan; 28(3):310-331. PubMed ID: 35110952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational HCC screening approaches for patients with NAFLD.
    Singal AG; El-Serag HB
    J Hepatol; 2022 Jan; 76(1):195-201. PubMed ID: 34508791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Cernea S; Onișor D
    World J Gastroenterol; 2023 Jan; 29(2):286-309. PubMed ID: 36687124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis.
    Tovo CV; de Mattos AZ; Coral GP; Sartori GDP; Nogueira LV; Both GT; Villela-Nogueira CA; de Mattos AA
    World J Gastroenterol; 2023 Jan; 29(2):343-356. PubMed ID: 36687125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.